Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.56 |
| ▸ | PARP1 | P09874 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24680794 | 0.93 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL15466514 | 0.85 | PARP10 (0.62) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL15727828 | 0.82 | CLK4 (0.46) | PARP10PARP11PARP1GRM5 | |
| SCHEMBL30013219 | 0.82 | CLK4 (0.46) | PARP10PARP11PARP1GRM5 | |
| SCHEMBL30285367 | 0.79 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL21333738 | 0.79 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL12559528 | 0.79 | GRM5 (0.59) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL17073495 | 0.79 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL23865194 | 0.79 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 | |
| SCHEMBL4500561 | 0.79 | PARP10 (0.56) | PARP10PARP11PARP1KDM4EF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999716-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218051-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | PARP10 1423/4885PARP11 790/4885PARP1 972/4885 |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | PARP10 501/4885PARP11 487/4885PARP1 1588/4885 |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | PARP10 1423/4885PARP11 790/4885PARP1 972/4885 |
| US-11999716-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | PARP10 555/4885PARP11 553/4885PARP1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.